Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 1/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.70 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.70 |
| ▸ | ENPP2 | Q13822 | 5/20 | 0.67 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.67 |
| ▸ | PRKCA | P17252 | 4/20 | 0.67 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.67 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.67 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.67 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphocholine SCHEMBL26629479 | 1.00 | FABP3 (0.74) | FABP3SMN1; SMN2NR5A2NR5A1ENPP2 | |
| Phosphocholine SCHEMBL16102973 | 1.00 | FABP3 (0.74) | FABP3SMN1; SMN2NR5A2NR5A1ENPP2 | |
| Phosphocholine SCHEMBL480378 | 1.00 | FABP3 (0.74) | FABP3SMN1; SMN2NR5A2NR5A1ENPP2 | |
| 1,2-Dipalmitin SCHEMBL25387086 | 0.99 | FABP3 (0.73) | FABP3SMN1; SMN2NR5A2NR5A1ENPP2 | |
| Diolein SCHEMBL16100175 | 0.94 | PRKCA (0.71) | FABP3SMN1; SMN2NR5A2NR5A1ENPP2 | |
| Phosphocholine SCHEMBL18114342 | 0.91 | SMN1; SMN2 (0.74) | FABP3SMN1; SMN2NR5A2NR5A1ENPP2 | |
| 1,2-Dipalmitin SCHEMBL4326807 | 0.91 | SMN1; SMN2 (0.74) | FABP3SMN1; SMN2NR5A2NR5A1ENPP2 | |
| Phosphocholine SCHEMBL18114371 | 0.91 | SMN1; SMN2 (0.74) | FABP3SMN1; SMN2NR5A2NR5A1ENPP2 | |
| Phosphocholine SCHEMBL3654560 | 0.91 | SMN1; SMN2 (0.74) | FABP3SMN1; SMN2NR5A2NR5A1ENPP2 | |
| Phosphocholine SCHEMBL3963371 | 0.91 | SMN1; SMN2 (0.74) | FABP3SMN1; SMN2NR5A2NR5A1ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1255563-B2 | COMPOSITION OF ANTIGEN AND GLYCOLIPID ADJUVANT FOR SUBLINGUAL ADMINISTRATION | ALLERGY THERAPEUTICS UK LTD (GB) | 2016-03-02 | — | — | EP | disclosed |
| EP-2100616-B1 | Composition of antigen and glycolipid adjuvant for sublingual administration | ALLERGY THERAPEUTICS UK LTD (GB) | 2015-11-25 | — | — | EP | disclosed |
| US-8470331-B2 | Induce immunology response; antiallergens; bioavailability; autoimmune disease, anticancer agents, antiallergens | ALLERGY THERAPEUTICS (UK) LIMITED (GB) | 2013-06-25 | — | — | US | disclosed |
| EP-2322212-A1 | Compositon of antigen and glycolipid adjuvant for sublingual administration | Allergy Therapeutics (UK) Limited (GB) | 2011-05-18 | — | — | EP | disclosed |
| US-7815920-B2 | Method of preparing an antigen-containing formulation | Allergy Therapeutics (UK) Ltd (GB) | 2010-10-19 | — | — | US | disclosed |
| EP-2100616-A2 | Composition of antigen and glycolipid adjuvant sublingual administration | Allergy Therapeutics (UK) Limited (GB) | 2009-09-16 | — | — | EP | disclosed |
| EP-1255563-B1 | COMPOSITION OF ANTIGEN AND GLYCOLIPID ADJUVANT SUBLINGUAL ADMINISTRATION | ALLERGY THERAPEUTICS UK LTD (GB) | 2009-07-22 | — | — | EP | disclosed |
| EP-0988862-B1 | Formulation comprising an antigen, a TH-1 inducing adjuvant and a sparingly water soluble amino acid for use in immunisation | ALLERGY THERAPEUTICS LTD (GB) | 2006-11-29 | — | — | EP | disclosed |
| EP-0975364-B1 | ALLERGEN FORMULATION | ALLERGY THERAPEUTICS LTD (GB) | 2004-06-09 | — | — | EP | disclosed |
| US-20030165512-A1 | Composition of antigen and glycolipid adjuvant for sublingual administration | ALLERGY THERAPEUTICS (UK) LIMITED (GB) | 2003-09-04 | — | — | US | disclosed |
| US-20030007977-A1 | Method of preparing an antigen-containing formulation | WHEELER ALAN (US) | 2003-01-09 | — | — | US | disclosed |
| EP-1255563-A1 | COMPOSITION OF ANTIGEN AND GLYCOLIPID ADJUVANT SUBLINGUAL ADMINISTRATION | Allergy Therapeutics Limited (GB) | 2002-11-13 | — | — | EP | disclosed |
| US-6440426-B1 | ANTIGEN, MONOPHOSPHORYL LIPID A, AND TYROSINE; VACCINES | ALLERGY THERAPEUTICS LIMITED (GB) | 2002-08-27 | — | — | US | disclosed |
| WO-2001051082-A1 | COMPOSITION OF ANTIGEN AND GLYCOLIPID ADJUVANT SUBLINGUAL ADMINISTRATION | ALLERGY THERAPEUTICS LIMITED (GB) | 2001-07-19 | — | — | WO | disclosed |
| EP-0988862-A2 | Formulation for use in immunisation | Allergy Therapeutics Limited (GB) | 2000-03-29 | — | — | EP | disclosed |
| EP-0975364-A1 | ALLERGEN FORMULATION | Allergy Therapeutics Limited (GB) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998044947-A1 | ALLERGEN FORMULATION | ALLERGY THERAPEUTICS LIMITED (GB) | 1998-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030007977-A1 | Method of preparing an antigen-containing formulation | CD69, CD14, TYR | FABP3 271/4885SMN1; SMN2 4789/4885NR5A2 3644/4885 |
| US-20030165512-A1 | Composition of antigen and glycolipid adjuvant for sublingual administration | LY96, CD69, MUC1 | FABP3 212/4885SMN1; SMN2 3695/4885NR5A2 2563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.